Elevation Oncology develops selective cancer therapies tailored to individual tumor characteristics, targeting solid tumors with significant unmet medical needs. The company focuses on precision medicine to provide patients with treatments that are specifically matched to the molecular drivers of their cancer.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies lack specificity, leading to off-target effects and limited efficacy across diverse solid tumors. A significant unmet need exists for treatments that precisely target the molecular drivers of individual tumors, maximizing therapeutic benefit while minimizing harm to healthy tissues.
Solution
Elevation Oncology develops selective cancer therapies designed to target specific molecular characteristics of individual tumors. The company focuses on identifying and developing innovative therapies that can be matched to a patient's unique tumor profile. By employing a precision medicine approach, Elevation Oncology aims to provide more effective and targeted treatments for patients with solid tumors, addressing significant unmet needs in cancer care. This strategy seeks to improve patient outcomes by selectively targeting the mechanisms driving cancer growth.
Target Audience
The primary target audience includes cancer patients with solid tumors who could benefit from precision medicine approaches, as well as oncologists seeking more targeted and effective treatment options.
Features
- Focus on the discovery and development of selective cancer therapies.
- Therapies are matched to a patient’s unique tumor characteristics.
- Pipeline targets a range of solid tumors with significant unmet medical needs.